Cart
sales@molnova.com
SW-106065
CAS No. 62289-81-0
SW-106065 ( SW106065;MPNST-IN-21 )
Catalog No. M15357 CAS No. 62289-81-0
SW-106065 is a novel pharmacologic inducer of apoptosis in MPNST (malignant peripheral nerve sheath tumors).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 57 | Get Quote |
|
| 5MG | 98 | Get Quote |
|
| 10MG | 155 | Get Quote |
|
| 25MG | 282 | Get Quote |
|
| 50MG | 444 | Get Quote |
|
| 100MG | 653 | Get Quote |
|
| 500MG | 1368 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameSW-106065
-
NoteResearch use only, not for human use.
-
Brief DescriptionSW-106065 is a novel pharmacologic inducer of apoptosis in MPNST (malignant peripheral nerve sheath tumors).
-
DescriptionSW-106065 is a novel pharmacologic inducer of apoptosis in MPNST (malignant peripheral nerve sheath tumors); inhibits ATP consumption of sMPNST and other models of MPNST with EC50 of 1 uM, shows no toxicity to normally dividing Schwann cells or mouse embryonic fibroblasts; reduces MPNST burden in a mouse allograft model.
-
SynonymsSW106065;MPNST-IN-21
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorApoptosis
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number62289-81-0
-
Formula Weight204.25
-
Molecular FormulaC10H8N2OS
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC1=CC(=CN=C1)NC(=O)C2=CC=CS2
-
Chemical NameN-(pyridin-3-yl)thiophene-2-carboxamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Chau V, et al. Cancer Res. 2014 Jan 15;74(2):586-97.
molnova catalog
related products
-
UCF 101
UCF 101 is a specific inhibitor of HtrA2 and reduces apoptosis in PC12 cells.
-
Millepachine
Millepachine is a natural product found in the Chinese herbal medicine with strong antitumor effects against numerous human cancer cells.
-
Eriocalyxin B
Eriocalyxin B induces apoptosis and cell cycle arrest in pancreatic adenocarcinoma cells through caspase- and p53-dependent pathways, should be considered a candidate for pancreatic cancer treatment.
